Mereo BioPharma Group plc (MREO)
MREO Stock Price Chart
Explore Mereo BioPharma Group plc interactive price chart. Choose custom timeframes to analyze MREO price movements and trends.
MREO Company Profile
Discover essential business fundamentals and corporate details for Mereo BioPharma Group plc (MREO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Apr 2019
Employees
36.00
Website
https://www.mereobiopharma.comCEO
Denise Vera Scots-Knight
Description
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Financial Timeline
Browse a chronological timeline of Mereo BioPharma Group plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $3.50m.
Earnings released on 12 May 2026
EPS came in at -$0.01 falling short of the estimated $0.02 by -150.00%.
Earnings released on 19 Mar 2026
EPS came in at -$0.01 matching the estimated -$0.01.
Earnings released on 10 Nov 2025
EPS came in at -$0.01 falling short of the estimated -$0.01 by -20.05%, while revenue for the quarter reached $300.00k , missing expectations by -94.34%.
Earnings released on 12 Aug 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $685.71k .
Earnings released on 13 May 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%.
Earnings released on 26 Mar 2025
EPS came in at -$0.01 surpassing the estimated -$0.02 by +50.00%, while revenue for the quarter reached $1.33m , missing expectations by -88.80%.
Earnings released on 12 Nov 2024
EPS came in at -$7.69 falling short of the estimated -$1.36 by -465.44%.
Earnings released on 13 Aug 2024
EPS came in at -$0.02 surpassing the estimated -$0.78 by +97.44%.
Earnings released on 15 May 2024
EPS came in at -$0.01 .
Earnings released on 27 Mar 2024
EPS came in at -$0.01 surpassing the estimated -$0.02 by +44.75%, while revenue for the quarter reached $456.43k .
Earnings released on 17 Nov 2023
EPS came in at -$0.01 , while revenue for the quarter reached $648.81k .
Earnings released on 7 Sept 2023
EPS came in at -$0.03 falling short of the estimated -$0.02 by -37.05%, while revenue for the quarter reached $11.13m .
Earnings released on 27 Jun 2023
EPS came in at -$0.01 , while revenue for the quarter reached $4.41m .
Earnings released on 28 Mar 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +28.87%, while revenue for the quarter reached $1.02m .
Earnings released on 2 Nov 2022
EPS came in at -$0.02 surpassing the estimated -$0.38 by +95.58%, while revenue for the quarter reached $746.79k .
Earnings released on 30 Jun 2022
EPS came in at -$0.05 .
Earnings released on 1 Apr 2022
EPS came in at $0.00 surpassing the estimated -$4.50 by +100.04%.
Earnings released on 31 Mar 2022
EPS came in at -$0.03 , while revenue for the quarter reached $606.46k .
Earnings released on 8 Nov 2021
EPS came in at $0.00 surpassing the estimated -$2.50 by +100.04%, while revenue for the quarter reached $416.83k .
MREO Stock Performance
Access detailed MREO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
